General
Preferred name
NORELGESTROMIN
Synonyms
17-Deacetyl norgestimate ()
17-Deacylnorgestimate ()
Norgestimate metabolite Norelgestromin ()
P&D ID
PD014375
CAS
53016-31-2
Tags
natural product
drug
available
Approved by
FDA
First approval
2001
Drug Status
investigational
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.;
Compound Sets
7
DrugBank
DB06713
DrugBank Approved Drugs
DB06713
DrugCentral
1959
DrugCentral Approved Drugs
1959
NCATS Inxight Approved Drugs
R0TAY3X631
NPC Screening Collection
TargetMol Bioactive Compound Library
T16338
External IDs
15
Properties
(calculated by RDKit )
Molecular Weight
327.22
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
0
cLogP
4.14
TPSA
52.82
Fraction CSP3
0.76
Chiral centers
6.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Target
Drug Metabolite
Source data